Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted market
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of “Moderate Buy” by Analysts
01:11am, Monday, 22'nd Dec 2025
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the company, MarketBeat reports. O
KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript
10:53am, Monday, 24'th Nov 2025
KalVista Pharmaceuticals, Inc. ( KALV ) Jefferies London Healthcare Conference 2025 November 19, 2025 8:30 AM EST Company Participants Benjamin Palleiko - CEO & Director Conference Call Participants M
Investors Buy Large Volume of KalVista Pharmaceuticals Put Options (NASDAQ:KALV)
01:10am, Wednesday, 12'th Nov 2025
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 5,001 put options on the stock. This represents an increase of 613% comp
KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript
01:41pm, Tuesday, 11'th Nov 2025
KalVista Pharmaceuticals, Inc. ( KALV ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Paul Audhya
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates
07:56pm, Monday, 10'th Nov 2025
KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.91 per share a year ago.
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
04:30pm, Monday, 10'th Nov 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and reported financial results for the third quarter ended
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new patient satisfaction and pediatrics data from its clinical studies of EKTERLY
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
07:00am, Wednesday, 05'th Nov 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following up
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
07:00am, Monday, 03'rd Nov 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat),
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
07:00am, Monday, 06'th Oct 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chi
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 03'rd Oct 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted two new
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
07:00am, Thursday, 02'nd Oct 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress
07:00am, Friday, 26'th Sep 2025
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20th German Aller
